Clinical Trials Browser

Phase 2 × Has announcements × Neuroblastoma × Clear all

NCT03363373 2026-02-19

Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow

Phase 2 Recruiting

122 enrolled 2 FDA

Neuroblastoma

NCT02395666 2024-08-06

Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remission

Phase 2 Completed

140 enrolled 14 charts 1 FDA

Neuroblastoma